Gregory Gene Freitag - 11 Jul 2025 Form 4 Insider Report for ZyVersa Therapeutics, Inc. (ZVSA)

Reporting relationship: Director
Issuer ticker: ZVSA
Reported as of: 11 Jul 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Jul 2025, 16:22:57 UTC
Prior SEC filing: 11 Jun 2025
Next SEC filing: 03 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Stephen C. Glover as Attorney-in-Fact for Gregory Freitag pursuant to Power of Attorney

Key filing fact

Gregory Gene Freitag filed Form 4 for ZyVersa Therapeutics, Inc. (ZVSA) on 15 Jul 2025.

Key facts

This page summarizes Gregory Gene Freitag's Form 4 filing for ZyVersa Therapeutics, Inc. (ZVSA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 15 Jul 2025, 16:22.

Change

Previous filing in this sequence was filed on 11 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001492710 Primary reporting owner

Freitag Gregory Gene

Relationship: Director
Address: C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, SUITE 208, WESTON
Signature: /s/ Stephen C. Glover as Attorney-in-Fact for Gregory Freitag pursuant to Power of Attorney
Signature date: 14 Jul 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ZVSA transaction Derivative

Stock Options

Award

Transaction value: $0
Shares: +11,066
Change %
Price: $0.000000
Shares after: 11,066
Date: 11 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 11,066
Exercise price: $0.5900
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The options were granted on July 11, 2025, and vest and become exercisable in equal annual installments on the first three anniversaries of the grant date, subject to the Reporting Person's continued service on each such vesting date.